The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2022 | The role of chemoimmunotherapy in the era of targeted therapies for CLL
Lukas Smolej, MD, PhD, Charles University, Hradec Králové, Czech Republic, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia (CLL). Dr Smolej explains that whilst chemoimmunotherapy is not a viable option in the relapsed/refractory (R/R) setting where targeted agents are now the standard of care (SOC), it may still be used in patients with favorable prognostic markers including patients with mutated IGHV in the frontline setting. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
